The successor to the hearing aid
Not amplification — intention. CortiSleeve is a neurally-steered sleeve that retrofits the earbuds you already own, decoding who you're listening to and bringing that voice forward. We don't just amplify sound. We decode your focus.
Slide to focus — one voice rises, the room falls away.
The problem
Traditional hearing aids amplify everything. In a crowded room they fail, because they don't know who you mean to listen to — it's indiscriminate amplification, the decades-old challenge engineers call the Cocktail Party Problem. For 1.5 billion people with hearing loss, it turns a dinner table into exhausting noise, and many choose silence instead.
Current hearing aids and ANC earbuds amplify or cancel indiscriminately. They can't distinguish the voice that matters from the noise that doesn't.
Amplification without intent floods the listener. Crowded rooms become fatiguing rather than social — so the technology gets left in the drawer.
A walled-garden industry of high margins and low innovation keeps clinical-grade clarity behind cost and stigma.
The device
We don't replace your hardware — we upgrade it. A flexible sleeve retrofits onto the Sony, Apple or Bose earbuds you already own, adding brain-computer interface capability that identifies the voice you want and suppresses the rest.
A removable, flexible sleeve built for standard ear-worn audio devices. Add neural intelligence to the premium earbuds you already love and wear — no new hardware to buy, no clinic visit.
Neural steering lets you lock onto the voice that matters — in a meeting, a call, or a crowded restaurant — and lets the AI handle the heavy lifting of sound filtration so you stay mentally sharp.
Navigate dinner parties and busy restaurants without missing a word — back to the restaurant, the family table, the connection.
Lock onto a colleague's voice in a noisy meeting room without straining, and minimise nearby whispers and keyboard tapping.
High-fidelity clarity in lecture halls and auditoriums — reduced listening fatigue, every word in focus.
The moat
The barrier to in-ear EEG isn't software — it's electromagnetic interference from the earbud driver, millimetres from the electrode. Our patent-pending Mu-Metal shielding is the only architecture that captures clean, clinical-grade EEG from a standard earbud stem without that interference.
High-fidelity EEG from the ear canal — dry electrodes, no gel, no preparation.
High-permeability Mu-Metal laminate blocks Bluetooth and driver EM fields that mask neural signals.
On-device decoding keeps latency low and your raw neural data private — it never leaves the sleeve.
Patent pending in the UK & US; UK trademark registered. The defensible barrier against competitors.
Dry-electrode EEG reads cortical rhythms from the ear canal.
Signal: micro-volt (μV)
Mu-Metal shielding strips driver and Bluetooth interference at the source.
Shielding: high-permeability
A real-time correlation engine matches brain rhythms to the speaker's voice signature.
Auditory Attention Decoding
The companion app boosts the target voice and suppresses background noise.
Target: +14 dB SNR
Performance figures are engineering design targets, to be confirmed in our independent validation study.
The opportunity
The hearing-aid industry is controlled by a handful of companies relying on high margins and low innovation. CortiSleeve removes the barrier to entry with software-defined hearing — sold first as a consumer accessory, with no medical certification required to reach early adopters.
people worldwide live with hearing loss — many seeking a non-stigmatised, intent-aware alternative.
incumbent hearing-aid market, priced at £5,000+ per device. We enter as an affordable retrofit.
direct-to-consumer first — professionals and students — then clinical certification and OEM licensing.
Market figures are drawn from public industry estimates and should be independently verified.
Roadmap
UK trademark registered; patents filed in UK and US.
MVP hardware build and an independent N=5 validation study proving SNR gains in real environments.
Limited release to early adopters; AAD algorithms and UX refined with real-world data.
MHRA pathway begins; OEM licensing partnerships established.
Beyond hearing
LONG-TERM VISIONHearing is the beachhead. The neural signal that picks a voice out of a crowd is, fundamentally, decoded human intent — and that intent can do more than tune audio. In time, the same sensor and signal chain could let people supervise AI agents and guide robots by focus rather than typed commands. We're building the hearing product first; the platform follows the validated science.
Decoding sub-conscious error-recognition could let a supervisor freeze a failing AI agent the instant they notice — no click, no command.
The human sets the goal by attention; the machine computes execution — guiding cobots by focus rather than joystick.
Delivered as a developer SDK, the decoded-intent stream becomes cognitive middleware for the agentic enterprise.
This section describes a future research direction, not a current product.
Team
Alfred is CIO of CPL Aromas and Founder of Nevodia Tech — a recognised leader in AI-native enterprise transformation. He is the inventor of the patent-pending CortiSleeve architecture and has built a portfolio of live AI SaaS platforms across compliance, audit and autonomous-agent automation. He is a passionate advocate for democratising AI so organisations can scale intelligence.
linkedin.com/in/alfredsunilRaj is a visionary product leader and founder with deep expertise at the intersection of embodied AI, autonomous systems and advanced computing. He is Founder & CEO of NextDrive AI Inc., building next-generation infrastructure for physical AI systems — spanning autonomous vehicles, intelligent robotics, central compute platforms and electric mobility.
linkedin.com/in/reddyrajeshFunding
We fund the binary physics question first — does the sleeve capture clean intent? — then build on its answer.
Proves the hearing product.
Scales the launch and opens the platform — priced on validation data.
Information on this page is provided for general interest and does not constitute an offer or financial promotion. Investment in early-stage companies places your capital at risk.